ACOR logo

Acorda Therapeutics (ACOR) Cash From Operations

Annual CFO

-$13.98 M
+$6.94 M+33.17%

December 31, 2023

Summary

Performance

1-Year Change

+33.17%

3-Year Change

+77.08%

5-Year Change

-109.27%

15-Year Change

-114.4%

ACOR Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$150.79 M
ACOR annual cash flow from operations is currently -109.27% below its historical high of $150.79 million

3-Year Low

-$41.35 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
ACOR previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

N/A
ACOR next annual earnings announcement has not yet been scheduled

OtherACORcash flowmetrics:

Annual CFI

-$264.00 K
ACOR annual cash flow from investing activities is -$264.00 thousand

Annual CFF

$0.00
ACOR annual cash flow from financing activities is $0.00

Annual FCF

-$14.25 M
ACOR annual free cash flow is -$14.25 million

Annual CAPEX

$264.00 K
ACOR annual capital expenditures is $264.00 thousand

Quarterly CFO

-$20.18 M
-$17.17 M-568.82%

March 31, 2024

Summary

Performance

3-Month Change

-568.82%

1-Year Change

-187.62%

3-Year Change

+24.93%

5-Year Change

+73.95%

ACOR Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$82.29 M
ACOR quarterly cash flow from operations is currently -124.53% below its historical high of $82.29 million

3-Year Low

-$20.18 M
ACOR quarterly cash flow from operations is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Mar 31, 2024
ACOR previous earnings announcement was published on Mar 31, 2024

Next Quarterly Earnings Report Date

N/A
ACOR next earnings announcement has not yet been scheduled

OtherACORcash flowmetrics:

Quarterly CFI

$0.00
ACOR quarterly cash flow from investing activities is $0.00

Quarterly CFF

-
ACOR quarterly cash flow from financing activities value is unknown

Quarterly FCF

-$20.18 M
ACOR quarterly free cash flow is -$20.18 million

Quarterly CAPEX

-
ACOR quarterly capital expenditures value is unknown

TTM CFO

-$27.15 M
-$13.17 M-94.16%

March 31, 2024

Summary

Performance

3-Month Change

-94.16%

1-Year Change

-89.8%

3-Year Change

+44.72%

5-Year Change

+78.82%

ACOR TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$223.66 M
ACOR TTM cash flow from operations is currently -112.14% below its historical high of $223.66 million

3-Year Low

-$41.35 M

Earnings dates

Last Quarterly Earnings Report Date

Mar 31, 2024
ACOR previous earnings announcement was published on Mar 31, 2024

Next Quarterly Earnings Report Date

N/A
ACOR next earnings announcement has not yet been scheduled

OtherACORcash flowmetrics:

TTM CFI

-$264.00 K
ACOR TTM cash flow from investing activities is -$264.00 thousand

TTM CFF

-
ACOR TTM cash flow from financing activities value is unknown

TTM FCF

-$27.41 M
ACOR TTM free cash flow is -$27.41 million

TTM CAPEX

-
ACOR TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

ACOR Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+33.2%-187.6%-89.8%
3 y3 years+77.1%+24.9%+44.7%
5 y5 years-109.3%+74.0%+78.8%

ACOR Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+195.7%-322.6%at low+1329.0%+52.3%
5 y5-yearat high+816.5%-322.6%+92.1%+1329.0%+372.1%
alltimeall time-109.3%+816.5%-124.5%+283.9%-112.1%+375.4%

Acorda Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Mar 2024
-
-$20.18 M(+568.8%)
-$27.15 M(+94.2%)
Dec 2023
-$13.98 M(-33.2%)
-$3.02 M(-139.7%)
-$13.98 M(+636.0%)
Sep 2023
-
$7.61 M(-165.8%)
-$1.90 M(-83.3%)
Jun 2023
-
-$11.56 M(+64.7%)
-$11.35 M(-20.7%)
Mar 2023
-
-$7.02 M(-177.4%)
-$14.30 M(-31.6%)
Dec 2022
-$20.92 M(-49.4%)
$9.07 M(-593.0%)
-$20.92 M(-21.8%)
Sep 2022
-
-$1.84 M(-87.3%)
-$26.75 M(-21.1%)
Jun 2022
-
-$14.51 M(+6.4%)
-$33.92 M(+20.7%)
Mar 2022
-
-$13.64 M(-520.9%)
-$28.10 M(-32.0%)
Dec 2021
-$41.35 M(-32.2%)
$3.24 M(-136.0%)
-$41.35 M(-4.2%)
Sep 2021
-
-$9.01 M(+3.7%)
-$43.14 M(+16.5%)
Jun 2021
-
-$8.69 M(-67.7%)
-$37.03 M(-24.6%)
Mar 2021
-
-$26.89 M(-1956.9%)
-$49.12 M(-19.5%)
Dec 2020
-$61.01 M(-52.4%)
$1.45 M(-149.8%)
-$61.01 M(-17.4%)
Sep 2020
-
-$2.90 M(-86.0%)
-$73.88 M(-22.5%)
Jun 2020
-
-$20.77 M(-46.4%)
-$95.33 M(+6.6%)
Mar 2020
-
-$38.78 M(+239.3%)
-$89.45 M(-30.2%)
Dec 2019
-$128.17 M(-185.0%)
-$11.43 M(-53.1%)
-$128.17 M(-0.7%)
Sep 2019
-
-$24.35 M(+63.5%)
-$129.08 M(+386.1%)
Jun 2019
-
-$14.89 M(-80.8%)
-$26.55 M(-159.5%)
Mar 2019
-
-$77.50 M(+528.1%)
$44.60 M(-70.4%)
Dec 2018
$150.79 M(+55.2%)
-$12.34 M(-115.8%)
$150.79 M(-32.6%)
Sep 2018
-
$78.17 M(+39.0%)
$223.66 M(+13.4%)
Jun 2018
-
$56.26 M(+96.0%)
$197.25 M(+30.4%)
Mar 2018
-
$28.70 M(-52.6%)
$151.26 M(+55.7%)
Dec 2017
$97.14 M(+227.6%)
$60.53 M(+16.9%)
$97.14 M(+53.3%)
Sep 2017
-
$51.76 M(+404.6%)
$63.38 M(+265.5%)
Jun 2017
-
$10.26 M(-140.4%)
$17.34 M(-803.3%)
Mar 2017
-
-$25.42 M(-194.9%)
-$2.47 M(-108.3%)
Dec 2016
$29.65 M(-22.9%)
$26.78 M(+367.7%)
$29.65 M(+17.7%)
Sep 2016
-
$5.72 M(-159.9%)
$25.20 M(-39.5%)
Jun 2016
-
-$9.55 M(-242.6%)
$41.63 M(-23.5%)
Mar 2016
-
$6.70 M(-70.0%)
$54.43 M(+41.4%)
Dec 2015
$38.48 M(-48.5%)
$22.32 M(+0.8%)
$38.48 M(+31.0%)
Sep 2015
-
$22.16 M(+581.7%)
$29.37 M(-35.6%)
Jun 2015
-
$3.25 M(-135.1%)
$45.64 M(-25.3%)
Mar 2015
-
-$9.25 M(-170.0%)
$61.09 M(-18.2%)
Dec 2014
$74.65 M
$13.22 M(-65.6%)
$74.65 M(-7.4%)
DateAnnualQuarterlyTTM
Sep 2014
-
$38.42 M(+105.4%)
$80.62 M(+30.8%)
Jun 2014
-
$18.71 M(+334.5%)
$61.64 M(+20.3%)
Mar 2014
-
$4.30 M(-77.6%)
$51.24 M(+30.4%)
Dec 2013
$39.28 M(-24.6%)
$19.19 M(-1.3%)
$39.28 M(+6.6%)
Sep 2013
-
$19.44 M(+134.0%)
$36.84 M(-1.5%)
Jun 2013
-
$8.31 M(-208.5%)
$37.41 M(-9.8%)
Mar 2013
-
-$7.66 M(-145.7%)
$41.45 M(-20.5%)
Dec 2012
$52.12 M(-21.4%)
$16.74 M(-16.4%)
$52.12 M(-23.7%)
Sep 2012
-
$20.02 M(+62.1%)
$68.35 M(-25.0%)
Jun 2012
-
$12.35 M(+310.1%)
$91.09 M(+11.8%)
Mar 2012
-
$3.01 M(-90.9%)
$81.47 M(+22.8%)
Dec 2011
$66.34 M(-445.2%)
$32.97 M(-22.9%)
$66.34 M(+89.8%)
Sep 2011
-
$42.76 M(+1467.4%)
$34.95 M(+63.0%)
Jun 2011
-
$2.73 M(-122.5%)
$21.44 M(-393.3%)
Mar 2011
-
-$12.12 M(-863.4%)
-$7.31 M(-62.0%)
Dec 2010
-$19.21 M(-149.7%)
$1.59 M(-94.6%)
-$19.21 M(-43.0%)
Sep 2010
-
$29.25 M(-212.4%)
-$33.72 M(-274.5%)
Jun 2010
-
-$26.02 M(+8.3%)
$19.32 M(-43.4%)
Mar 2010
-
-$24.03 M(+86.0%)
$34.13 M(-11.6%)
Dec 2009
$38.63 M(-178.6%)
-$12.91 M(-115.7%)
$38.63 M(+11.8%)
Sep 2009
-
$82.29 M(-834.0%)
$34.55 M(-155.9%)
Jun 2009
-
-$11.21 M(-42.6%)
-$61.82 M(+4.7%)
Mar 2009
-
-$19.53 M(+14.9%)
-$59.03 M(+20.1%)
Dec 2008
-$49.16 M(+91.4%)
-$17.00 M(+20.6%)
-$49.16 M(+16.9%)
Sep 2008
-
-$14.09 M(+67.3%)
-$42.06 M(+27.9%)
Jun 2008
-
-$8.42 M(-12.8%)
-$32.88 M(+15.8%)
Mar 2008
-
-$9.65 M(-2.5%)
-$28.39 M(+10.6%)
Dec 2007
-$25.68 M(+9.4%)
-$9.90 M(+101.7%)
-$25.68 M(+81.9%)
Sep 2007
-
-$4.91 M(+25.0%)
-$14.12 M(-6.3%)
Jun 2007
-
-$3.93 M(-43.4%)
-$15.06 M(-2.0%)
Mar 2007
-
-$6.94 M(-518.8%)
-$15.37 M(-34.5%)
Dec 2006
-$23.46 M(+16.4%)
$1.66 M(-128.3%)
-$23.46 M(-6.6%)
Sep 2006
-
-$5.85 M(+38.2%)
-$25.12 M(+30.4%)
Jun 2006
-
-$4.24 M(-71.8%)
-$19.27 M(+28.2%)
Mar 2006
-
-$15.03 M(+99.0%)
-$15.03 M(+99.0%)
Dec 2005
-$20.15 M(-25.2%)
-
-
Dec 2004
-$26.94 M(+10.0%)
-
-
Sep 2003
-
-$7.55 M
-$7.55 M
Jun 2003
-$24.49 M
-
-

FAQ

  • What is Acorda Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Acorda Therapeutics?
  • What is Acorda Therapeutics annual CFO year-on-year change?
  • What is Acorda Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Acorda Therapeutics?
  • What is Acorda Therapeutics quarterly CFO year-on-year change?
  • What is Acorda Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Acorda Therapeutics?
  • What is Acorda Therapeutics TTM CFO year-on-year change?

What is Acorda Therapeutics annual cash flow from operations?

The current annual CFO of ACOR is -$13.98 M

What is the all time high annual CFO for Acorda Therapeutics?

Acorda Therapeutics all-time high annual cash flow from operations is $150.79 M

What is Acorda Therapeutics annual CFO year-on-year change?

Over the past year, ACOR annual cash flow from operations has changed by +$6.94 M (+33.17%)

What is Acorda Therapeutics quarterly cash flow from operations?

The current quarterly CFO of ACOR is -$20.18 M

What is the all time high quarterly CFO for Acorda Therapeutics?

Acorda Therapeutics all-time high quarterly cash flow from operations is $82.29 M

What is Acorda Therapeutics quarterly CFO year-on-year change?

Over the past year, ACOR quarterly cash flow from operations has changed by -$13.17 M (-187.62%)

What is Acorda Therapeutics TTM cash flow from operations?

The current TTM CFO of ACOR is -$27.15 M

What is the all time high TTM CFO for Acorda Therapeutics?

Acorda Therapeutics all-time high TTM cash flow from operations is $223.66 M

What is Acorda Therapeutics TTM CFO year-on-year change?

Over the past year, ACOR TTM cash flow from operations has changed by -$12.85 M (-89.80%)